Health
STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming
Publication: STAT
Author: Adam Feuerstein
Source published: 20/11/2026, 23:43:53 UTC
Briefing created: 21/11/2026, 01:50:22 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 21/11/2026, 00:37:23 UTC.
Briefings
The FDA rejected Capricor Therapeutics’ deramiocel cell therapy for Duchenne muscular dystrophy after two clinical trials failed to show efficacy in stopping heart failure or preserving muscle function in teenage patients. This rejection marks a significant setback for a promising treatment that had been in development for years, highlighting the regulatory challenges in treating this progressive disease.
Key points
- The FDA blocked deramiocel, a cell therapy for Duchenne muscular dystrophy, after two randomized clinical trials failed to demonstrate efficacy in stopping heart failure or preserving muscle function in teenage patients.
- Capricor Therapeutics developed deramiocel, which was intended for teenagers and young men with Duchenne who had lost the ability to walk, but the therapy did not help them.
Context
This rejection occurs in the context of Duchenne muscular dystrophy, a progressive muscle-wasting disease with few treatment options for teenagers and young men. Capricor conducted two randomized clinical trials, both of which failed to show deramiocel could stave off heart failure or preserve muscle function in their arms. The decision to block the treatment should have been straightforward, yet the regulatory process for this disease remains complex.
Limitations
The evidence is limited to the FDA rejection announcement from November 2026, with no additional data on the therapy’s long-term safety or efficacy. The source does not provide details on the specific number of patients treated, the duration of the trials, or the specific reasons for the regulatory hurdles beyond the failure of the two trials.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 21/11/2026, 01:50:22 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeib26vydumildzhyz2pnimqwqry73pqbxf7hafrf2stfm6shrgapxi